John‐John B. Schnog

4.3k total citations
50 papers, 1.4k citations indexed

About

John‐John B. Schnog is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, John‐John B. Schnog has authored 50 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Genetics, 28 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in John‐John B. Schnog's work include Hemoglobinopathies and Related Disorders (38 papers), Iron Metabolism and Disorders (20 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). John‐John B. Schnog is often cited by papers focused on Hemoglobinopathies and Related Disorders (38 papers), Iron Metabolism and Disorders (20 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). John‐John B. Schnog collaborates with scholars based in Netherlands, Curacao and United States. John‐John B. Schnog's co-authors include Ashley J. Duits, Dees P. M. Brandjes, Frits A.J. Muskiet, Bart J. Biemond, Erfan Nur, R.A. Rojer, Hans‐Martin Otten, Hugo Ten Cate, Fey P.L. van der Dijs and Tom Teerlink and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

John‐John B. Schnog

46 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John‐John B. Schnog Netherlands 24 1.0k 757 280 265 119 50 1.4k
Eduard J. van Beers Netherlands 25 940 0.9× 783 1.0× 619 2.2× 284 1.1× 248 2.1× 109 1.6k
Peter Gillette United States 18 1.4k 1.4× 1.1k 1.4× 299 1.1× 327 1.2× 451 3.8× 42 2.0k
Filomena Longo Italy 22 1.2k 1.2× 1.2k 1.6× 152 0.5× 193 0.7× 219 1.8× 90 2.0k
Fabiana Busti Italy 21 540 0.5× 773 1.0× 109 0.4× 170 0.6× 22 0.2× 47 1.3k
A. D. Stephens United Kingdom 20 671 0.6× 503 0.7× 122 0.4× 198 0.7× 288 2.4× 47 1.3k
Ashutosh Lal United States 20 679 0.7× 586 0.8× 216 0.8× 210 0.8× 232 1.9× 78 1.2k
Catherine Leiendecker‐Foster United States 17 746 0.7× 919 1.2× 151 0.5× 83 0.3× 51 0.4× 32 1.5k
Andrea U. Steinbicker Germany 17 429 0.4× 549 0.7× 139 0.5× 139 0.5× 42 0.4× 67 1.1k
P. Hopmeier Austria 16 295 0.3× 375 0.5× 76 0.3× 76 0.3× 127 1.1× 41 852
Takahiro Kuragano Japan 21 382 0.4× 708 0.9× 79 0.3× 83 0.3× 35 0.3× 62 1.2k

Countries citing papers authored by John‐John B. Schnog

Since Specialization
Citations

This map shows the geographic impact of John‐John B. Schnog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John‐John B. Schnog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John‐John B. Schnog more than expected).

Fields of papers citing papers by John‐John B. Schnog

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John‐John B. Schnog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John‐John B. Schnog. The network helps show where John‐John B. Schnog may publish in the future.

Co-authorship network of co-authors of John‐John B. Schnog

This figure shows the co-authorship network connecting the top 25 collaborators of John‐John B. Schnog. A scholar is included among the top collaborators of John‐John B. Schnog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John‐John B. Schnog. John‐John B. Schnog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duits, Ashley J., et al.. (2024). Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands. Journal of Cancer Policy. 41. 100493–100493. 2 indexed citations
2.
Schnog, John‐John B., Ashley J. Duits, & Michael Samson. (2024). Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit. SHILAP Revista de lepidopterología. 2(1). 45–45. 3 indexed citations
3.
Schnog, John‐John B., et al.. (2023). Untoward global effects of current guideline formulation of stereotactic radiotherapy for symptomatic brain metastases by international medical societies. The Lancet Regional Health - Americas. 25. 100584–100584.
4.
Schnog, John‐John B., Michael Samson, Rijk O. B. Gans, & Ashley J. Duits. (2021). An urgent call to raise the bar in oncology. British Journal of Cancer. 125(11). 1477–1485. 41 indexed citations
5.
Gerrits, Esther G. & John‐John B. Schnog. (2015). An unusual craving!. PubMed. 73(2). 96–96. 2 indexed citations
6.
Nur, Erfan, Bart J. Biemond, G J van Mierlo, et al.. (2013). Nucleosomes and neutrophil activation in sickle cell disease painful crisis. Haematologica. 98(11). 1797–1803. 61 indexed citations
7.
Nur, Erfan, Dees P. M. Brandjes, Tom Teerlink, et al.. (2012). N-acetylcysteine reduces oxidative stress in sickle cell patients. Annals of Hematology. 91(7). 1097–1105. 67 indexed citations
8.
Nur, Erfan, Dirk R. de Waart, John‐John B. Schnog, et al.. (2011). Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1812(11). 1412–1417. 38 indexed citations
9.
Nur, Erfan, et al.. (2011). Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. American Journal of Hematology. 86(6). 484–489. 162 indexed citations
10.
Nur, Erfan, Eduard J. van Beers, Ivan Cuccovillo, et al.. (2011). Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. Blood Cells Molecules and Diseases. 46(3). 189–194. 17 indexed citations
11.
Nur, Erfan, Bart J. Biemond, Anton P. van Zanten, et al.. (2010). Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. American Journal of Hematology. 85(11). 902–904. 15 indexed citations
12.
Nur, Erfan, Naomi I. Maria, Dees P. M. Brandjes, et al.. (2009). Elevated Circulating Stromal-Derived Factor-1 Levels in Sickle Cell Disease. Acta Haematologica. 122(1). 64–69. 8 indexed citations
13.
Beers, Eduard J. van, Berthe L.F. van Eck‐Smit, Melvin R. Mac Gillavry, et al.. (2008). Large and Medium-Sized Pulmonary Artery Obstruction Does Not Play a Role of Primary Importance in the Etiology of Sickle-Cell Disease-Associated Pulmonary Hypertension. CHEST Journal. 133(3). 646–652. 10 indexed citations
14.
Duits, Ashley J., et al.. (2006). Serum levels of angiogenic factors indicate a pro‐angiogenic state in adults with sickle cell disease. British Journal of Haematology. 134(1). 116–119. 39 indexed citations
15.
Schnog, John‐John B., Johanna A. Kremer Hovinga, Şakir Akın, et al.. (2006). ADAMTS13 activity in sickle cell disease. American Journal of Hematology. 81(7). 492–498. 48 indexed citations
16.
Schnog, John‐John B., et al.. (2004). Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Annals of Hematology. 83(6). 371–375. 67 indexed citations
17.
Schnog, John‐John B., et al.. (2004). Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Annals of Hematology. 84(5). 282–286. 56 indexed citations
18.
Dijs, Fey P.L. van der, M. Rebecca Fokkema, D.A. Janneke Dijck‐Brouwer, et al.. (2002). Optimization of folic acid, vitamin B12, and vitamin B6 supplements in pediatric patients with sickle cell disease. American Journal of Hematology. 69(4). 239–246. 23 indexed citations
19.
Schnog, John‐John B., Melvin R. Mac Gillavry, R.A. Rojer, et al.. (2002). No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. American Journal of Hematology. 71(1). 53–55. 8 indexed citations
20.
Schnog, John‐John B., Leroy R. Lard, R.A. Rojer, et al.. (1998). New concepts in assessing sickle cell disease severity. American Journal of Hematology. 58(1). 61–66. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eduard J. van Beers Breakdown of academic impact, for papers by Peter Gillette Breakdown of academic impact, for papers by Filomena Longo Breakdown of academic impact, for papers by Fabiana Busti Breakdown of academic impact, for papers by A. D. Stephens Breakdown of academic impact, for papers by Ashutosh Lal Breakdown of academic impact, for papers by Catherine Leiendecker‐Foster Breakdown of academic impact, for papers by Andrea U. Steinbicker Breakdown of academic impact, for papers by P. Hopmeier Breakdown of academic impact, for papers by Takahiro Kuragano
Rankless by CCL
2026